CATCH IR--CANDESARTAN IN AFRICAN AMERICANS W/ HYPERTENSION & INSULIN RESISTANCE

非裔美国人的靶器官疾病强调需要进一步研究这种疾病过程的潜在病理生理机制，以更有效地确定治疗方法。 我们假设，坎地沙坦西来昔酯，一种血管紧张素II受体阻滞剂，将减少高血压患者的血管肥大，从而改善骨骼肌的血管供应，骨骼肌是胰岛素抵抗的主要部位（研究A）。 骨骼肌血管供应的改变将促进骨骼肌纤维类型结构的进一步改变。 结果将是从基线至治疗结束时快肌与慢肌纤维比率增加，骨骼肌水平和全身代谢的胰岛素敏感性总体改善（研究B）。

Target end organ disease among African Americans emphasizes the need for further investigation into the underlying pathophysiologic mechanisms of this desease process to more effectively determine treatment. We hypothesize that Candesartan Cilexitil, an angiotensin II receptor blocker will reduce vascular hypertrophy in hypertensives and therefore improve vascular supply to skeletal muscle, the primary site for insulin resistance (Study A). The change in vascular supply to the skeletal muscle will promote a further change in the architecture of the skeletal muscle fiber type. The result will be an increase in the fast twitch to slow twitch fiber ratio from baseline to the end of treatment and an overall improvement in insulin sensitivity at the skeletal muscle level and whole body metabolism ( Study B).